The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

VI.b

Pulmonary arterial hypertension

Publications

Kay JM

Dietary pulmonary hypertension.

Thorax. 1994;49 Suppl(Suppl):S33-8

Tazelaar HD, Myers JL, Drage CW, King TE Jr, Aguayo S, Colby TV

Pulmonary disease associated with L-tryptophan-induced eosinophilic myalgia syndrome. Clinical and pathologic features.

Chest. 1990;97(5):1032-6

Yakovlevitch M, Siegel M, Hoch DH, Rutlen DL

Pulmonary hypertension in a patient with tryptophan-induced eosinophilia-myalgia syndrome.

The American journal of medicine. 1991;90(2):272-3

Campagna AC, Blanc PD, Criswell LA, Clarke D, Sack KE, Gold WM, Golden JA

Pulmonary manifestations of the eosinophilia-myalgia syndrome associated with tryptophan ingestion.

Chest. 1992;101(5):1274-81